Category Archives: Investment

Glaxo dodges another Advair punch as second generic attempt crashes; Big Pharma’s plight highlights new world order for competition and innovation

The News: GlaxoSmithKline PLC is likely to escape generic competition to its blockbuster lung drug Advair in the US this year, after a second application for a cut-price equivalent form… Read more »

Why Aeterna Zentaris got crushed, and is there any positive takeaway?

The News: Aeterna Zentaris Inc. (Nasdaq: AEZS) plunged 73% to $0.89 last week after announcing that the ZoptEC Phase 3 clinical study of Zoptrex (zoptarelin doxorubicin) in women with locally advanced,… Read more »

Pernix soars on absolutely no news; naturally, rumors of a takeout flourish

The News: Pernix Therapeutics Holdings Inc. (Nasdaq:PTX) was one of the week’s top gainers, rocketing $2.02, or 50%, to $6.33 Monday (May 8, 2017)–without a press release being issued, or other… Read more »

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?

The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

Molina Healthcare sacks founder’s sons; but don’t bet on a takeout

The News: Molina Healthcare Inc. (Long Beach CA) has fired its two top executives, sons of the medium-sized health insurer’s founder, in a surprise shakeup prompted by its poor financial… Read more »

Why Pacific Biosciences’ crash landing epitomizes the classic overreaction; now what

The News: Pacific Biosciences of California Inc. (Nasdaq:PACB) skidded $1.11, or 22% last week, to $3.94 in response to a wider-than-expected first-quarter loss. Wall Street was expecting the Menlo Park,… Read more »

Akebia shares soar on rich partnership with Otsuka; risky but rational gamble?

The News: Akebia Therapeutics Inc. (Nasdaq:AKBA) led advancing issues last week, soaring $4.08, or 45% for the 5-day stretch, to $13.18. The big move came after the Cambridge, MA-based company… Read more »

Anthem defies Wall Street, rivals, with stellar 1Q results pegged to Obamacare business

The News: Anthem Inc. (Indianapolis IN), which has 1.1 million customers in individual Obamacare plans, said it was moving ahead with its 2018 insurance filings but had told state regulators… Read more »

Novartis 1Q results remain insomnia cure; investors plead for something, anything to get excited about

The News: Novartis AG shares moved higher Tuesday (April 25, 2017) after the pharmaceuticals group clung to full-year earnings targets and barely beat analysts’ estimates for first-quarter earnings. The Swiss… Read more »

Week’s opening stock salvo: Cleveland BioLabs, ImmunoGen lead winners; XBiotech, OncoMed crash

Among the top winners and losers in the healthcare sector last week, the following four were standouts and bear watching or acting upon, depending, as always, on one’s risk tolerance…. Read more »